BREAKING NEWS
JULY 24, 2026 - The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.
Recommended FOR inclusion: (Yes-No)
• BPC-157 (8–6)
• KPV (8–6)
• TB-500 (8–6)
• MOTS-c (7–5)
• Epitalon (7–4)
• Semax (8–5)
Recommended AGAINST inclusion: (Yes-No)
• DSIP (6–7)
What happens next? These votes are advisory recommendations only. The FDA will now review the committee’s recommendations alongside the scientific record, public comments, and other regulatory considerations before making a final decision on whether these bulk drug substances will be included on the 503A Bulks List.
Note: Peptide names refer to all related bulk drug substances.
Learn More
Click here to learn more about the July 2026 PCAC meetings. For future updates like this, education, training, and support, explore what the SSRP community has to offer.